CTOs on the Move

Allogene

www.allogene.com

 
Allogene Therapeutics is a biotechnology company with a mission to catalyze the next revolution in cancer treatment through the development of allogeneic chimeric antigen receptor T-cell (CAR T) therapy directed at blood cancers and solid tumors. Founded and led by former Kite Pharma executives who bring unrivaled clinical development acumen in cell therapy, Allogene is well-positioned to further the potential of allogeneic cell therapy for patients. Allogeneic CAR T therapies are engineered from cells of healthy donors and stored for “off-the-shelf” use in patients. This approach eliminates the need to create personalized therapy from a patient`s own cells, simplifies manufacturing, ...
  • Number of Employees: 250-1000
  • Annual Revenue: $10-50 Million
  • www.allogene.com
  • 270 Littlefield Avenue
    South San Francisco, CA USA 94080
  • Phone: 650.457.2700

Executives

Name Title Contact Details
Nancy Saputra
 IT Director, Systems, Cloud, and Information Security Profile
Timothy Moore
 Chief Technical Officer Profile
Timothy Moore
 Chief Technology Officer Profile
Alison Moore
 Chief Technical Officer Profile
Alison Moore
 Executive Vice President of Operations and Chief Technical Officer Profile

Funding

Allogene raised $300M on 04/03/2018
Allogene raised $411.8M on 04/19/2018
Allogene raised $120M on 09/07/2018

Similar Companies

Sonoma Biotherapeutics

Sonoma Biotherapeutics is inventing the future of living therapies for autoimmune disease — safe, effective treatments as unique as each individual patient. Regulatory T cell therapies that harness a patient`s own immune cells, powerful next generation gene editing techniques and advanced manufacturing and quality assurance processes. Sonoma`s mission is to create a best-in-class regulatory T cell therapy that delivers long-lasting, highly efficacious treatments leading to cures across a spectrum of autoimmune and degenerative diseases.

Ikaria

Ikaria is one of the leading companies in the Healthcare, Pharmaceuticals, and Biotech sector.

RAPT Therapeutics

RAPT Therapeutics is a clinical stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in oncology and inflammatory diseases. Utilizing its proprietary discovery and development engine, the company develops highly selective small molecules that are designed to modulate the fundamental immune responses underlying these diseases. RAPT has rapidly discovered and advanced two unique drug candidates each targeting CCR4, including our lead oncology drug candidate, FLX475, now in clinical development and our lead inflammation drug candidate, RPT193, expected to enter the clinic in the second half of 2019. The company is also pursuing other discovery targets including GCN2 and HPK1 for the treatment of cancer.

Zymo Research Corporation

Zymo Research Corporation is a Irvine, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Replimune

Replimune is creating a new class of oncolytic immunotherapy designed to ignite a powerful immune response to treat cancer and vaccinate against future relapse. Replimune`s mission is to revolutionize cancer treatment with therapies designed to activate a powerful and durable full-body anti-tumor response. Replimune is pioneering the development of novel tumor-directed oncolytic immunotherapies. We imagine a world where cancer is a curable disease.